Lowcountry Infectious Diseases conducts clinical research and provides novel pharmaceutical therapies for many types of infectious diseases. The clinical research trials are conducted in our office or hospital setting to provide volunteers with access to treatment options that may not be available to the public.
Our Principal Investigator, Dr. Kent Stock, has been performing infectious disease research for over 30 years and personally oversees all clinical trial patients. He has managed clinical trials for the treatment of HIV/AIDS, gastrointestinal infections, upper and lower respiratory infections and many other conditions. If you are interested in learning more about our clinical research, our experienced research team can review your medical history with you to determine eligibility and answer all your questions.
Ask your Lowcountry ID provider if one of the following trials could benefit you.
ARISE - A randomized, double-blind, placebo-controlled, active comparator, multicenter study to validate patient-reported outcome instruments in adult subjects with newly diagnosed nontuberculous mycobacterial (NTM) lung infection caused by mycobacterium avium complex (MAC).
A phase 2/3, randomized, double-blind, placebo-controlled, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of orally administered epetraborole in patients with treatment-refractory mycobacterium avium complex lung disease (MACrO2).
A phase 2, randomized, double-blind, comparator-controlled, multicenter study to evaluate the safety and efficacy of CRS3123 compared with oral vancomycin in adults with clostridioides difficile infection.
A prospective, Phase 3, randomized, multi-center, double-blind, treatment-delay, placebo-controlled study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid tablets (500 mg/500 mg) for the treatment of uncomplicated urinary tract infections (uUTI) in adult women.
Double-blind, randomized, placebo-controlled, prospective phase III study evaluating efficacy and safety of panzyga in primary infection prophylaxis in patients with chronic lymphocytic leukemia ("pro-sid" study).
We just want to thank all of our patients, referring providers, and our community for bearing with us during this most difficult and unprecedented time in our infectious diseases' careers. Our providers and staff have been spread thin since COVID emerged, spending almost 100% of their time treating the severely ill in our community hospitals up and down the coast of South Carolina. We are doing our best to get back in the office as quickly as possible. Please help us get there quicker by getting vaccinated. Thank you for your patience.